title: Tolerance to the miotic effect of sarin vapor in rats after multiple low-level exposures.
abstract: Inhibition of acetylcholinesterase (AChE) by the organophosphorous compound sarin (GB) results in the accumulation of acetylcholine and excessive cholinergic stimulation. There are few data in the literature regarding the effects of multiple low-level exposures to GB and other organophosphorous compounds via relevant routes of exposure. Therefore, the present study was undertaken, and is the first, to investigate the effect of low-level repeated whole-body inhalation exposures to GB vapor on pupil size and cholinesterase activity in the eyes and blood. Male Sprague-Dawley rats were exposed to 4.0 mg/m3 of GB vapor for 1 h on each of 3 consecutive days. Pupil size and cholinesterase activities were determined at various points throughout the exposure sequence. The results demonstrate that multiple inhalation exposures to GB vapor produce a decrease in the miotic potency of GB in rats. This tolerance developed at a dose of GB that produced no overt signs of intoxication other than miosis. AChE and butyrylcholinesterase activity did not increase throughout the exposure sequence, suggesting that the tolerance cannot be attributed to a reduced inhibitory effect of GB. A decrease in the amount of GB present in the eye occurred after the third exposure. However, this change is insufficient to explain the tolerance, as there was no corresponding increase in AChE activity. Thus, the mechanism mediating the miotic tolerance observed after multiple inhalation exposures to the nerve agent GB remains uncertain, although several possibilities can be excluded based on the results of the present study.
authors.affiliation: National Research Council Postdoctoral Associate, National Academy of Sciences, Washington, DC, USA. paul.dabisch@us.army.mil
authors.forename: Paul A
authors.initials: PA
authors.lastname: Dabisch
authors.forename: David C
authors.initials: DC
authors.lastname: Burnett
authors.forename: Dennis B
authors.initials: DB
authors.lastname: Miller
authors.forename: Edward M
authors.initials: EM
authors.lastname: Jakubowski
authors.forename: William T
authors.initials: WT
authors.lastname: Muse
authors.forename: Jeffry S
authors.initials: JS
authors.lastname: Forster
authors.forename: Jacqueline A
authors.initials: JA
authors.lastname: Scotto
authors.forename: Jill R
authors.initials: JR
authors.lastname: Jarvis
authors.forename: Emily A
authors.initials: EA
authors.lastname: Davis
authors.forename: Stanley W
authors.initials: SW
authors.lastname: Hulet
authors.forename: Sharon A
authors.initials: SA
authors.lastname: Reutter
authors.forename: Robert J
authors.initials: RJ
authors.lastname: Mioduszewski
authors.forename: Sandra A
authors.initials: SA
authors.lastname: Thomson
mesh_terms: D000110:Acetylcholinesterase / Q000097:blood / Q000378:metabolism; D000280:Administration, Inhalation; D000818:Animals; D002091:Butyrylcholinesterase / Q000097:blood / Q000378:metabolism; D002800:Cholinesterase Inhibitors / Q000633:toxicity*; D004305:Dose-Response Relationship, Drug; D005123:Eye / Q000187:drug effects* / Q000201:enzymology; D008297:Male; D015877:Miosis / Q000139:chemically induced*; D051381:Rats; D017207:Rats, Sprague-Dawley; D012524:Sarin / Q000633:toxicity*; D014835:Volatilization
chemical_list: D002800:Cholinesterase Inhibitors; D012524:Sarin; D000110:Acetylcholinesterase; D002091:Butyrylcholinesterase